BMY vs PFE
Bristol Myers Squibb and Pfizer, both Healthcare
Pfizer is the larger company at $144B against $110B. On trailing earnings BMY is the cheaper of the two at a P/E of 14.9 against 37.3, a gap that is only a bargain if the two are growing at similar rates. Over the past year BMY returned +56% against +24% for PFE. Ryufin's sector-relative Smart Score puts BMY ahead, 9/10 against 7/10.
| Figure | BMY | PFE |
|---|---|---|
| Last close | $67.58 | $28.32 |
| Market cap | $110B | $144B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 14.9 | 37.3 |
| Dividend yield | 3.7% | 6.1% |
| 1-year return | +56% | +24% |
| 5-year return | +21% | -15% |
| Ryufin Smart Scoresector-relative, 1–10 | 9/10 | 7/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Bristol Myers Squibb
Revenue of $13B in Q2 2026, net income $3.3B. Its largest reported line is Eliquis, 34% of the disclosed total.
Pfizer
Revenue of $15B in Q2 2026, net income null. Its largest reported line is Eliquis, 15% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.